Does Allopurinol Benefit Patients With Cardiac Syndrome X?

This article originally appeared here.
No improvement in exercise capacity, coronary or peripheral endothelial function after six weeks
No improvement in exercise capacity, coronary or peripheral endothelial function after six weeks

(HealthDay News) — Allopurinol does not appear to improve exercise capacity or peripheral endothelial or coronary function in patients with cardiac syndrome X, according to a study published online Oct. 28 in Cardiovascular Therapeutics.

Tiong Keng Lim, M.D., from National Heart Centre Singapore, and colleagues randomized 19 patients with cardiac syndrome X (mean age 59 years) to six weeks of treatment with either allopurinol (600mg/day) or placebo. Patients were crossed over to the other study arm after a four-week washout period.

The researchers found that allopurinol significantly reduced serum uric acid levels versus placebo. There was no significant difference in maximum exercise time, coronary flow reserve, or flow-mediated vasodilatation of the brachial artery between the allopurinol and placebo groups. However, there was a trend toward allopurinol reducing serum B-type natriuretic peptide compared with placebo (P = 0.07).

Related Articles

"In patients with cardiac syndrome X, high dose allopurinol did not improve exercise capacity, coronary or peripheral endothelial function," conclude the authors.

Abstract
Full Text (subscription or payment may be required)